Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | SNCA | P37840 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402769 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL5530210 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL29358434 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Ubidecarenone SCHEMBL11901691 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Ubidecarenone SCHEMBL19858 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL16393869 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Coenzyme Q4 SCHEMBL6279408 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL9975753 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Ubidecarenone SCHEMBL13026488 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Coenzyme Q6 SCHEMBL29404151 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120060462-B | Neonate genetic disease screening gene combination, probe combination, kit, preparation method and device thereof | 东莞博奥木华基因科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2025231487-A1 | PHOTORECEPTOR SPECIFIC PROMOTORS FOR USE IN GENE THERAPIES FOR TREATMENT OF RETINAL DEGENERATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-11-06 | — | — | WO | claimed |
| US-20250262169-A1 | METHODS OF TREATING COENZYME Q10 DEFICIENCY | THLIVERIS, ANDREW T. | 2025-08-21 | — | — | US | claimed |
| WO-2025059302-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT AND MODULATION OF ACUTE AND CHRONIC SYMPTOMS OF MITOCHONDRIAL DISEASE AND DYSFUNCTION | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-03-20 | — | — | WO | claimed |
| CN-110869494-B | Without systemic immunosuppression allograft tolerance | 西奈卫生系统公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2025035032-A2 | METHODS AND COMPOSITIONS FOR PROVIDING CUSTOMIZED NUTRITIONAL SUPPLEMENTS | VIBRANT HOLDINGS, LLC (US) | 2025-02-13 | — | — | WO | claimed |
| US-20250000817-A1 | Methods of Treating Mitochondrial Dysfunction | RIBONOVA INC. (US) | 2025-01-02 | — | — | US | claimed |
| EP-3334484-B1 | COMPOSITIONS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR THE TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION | MASSACHUSETTS GEN HOSPITAL (US) | 2024-12-25 | — | — | EP | claimed |
| EP-4397369-A2 | METHODS OF TREATING MITOCHONDRIAL DYSFUNCTION | Ribonova Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230193205-A1 | GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS | FIGENE, LLC | 2023-06-22 | — | — | US | claimed |
| US-20230146253-A1 | METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-11 | — | — | US | claimed |
| EP-4162277-A1 | CELLULAR RESPONSE ASSAYS FOR LUNG CANCER | Precyte Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-23 | — | — | US | claimed |
| US-11579140-B2 | Methods related to bronchial premalignant lesion severity and progression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-02-14 | — | — | US | claimed |
| US-20220409554-A1 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | IC-MedTech Corp. | 2022-12-29 | — | — | US | claimed |
| US-11485743-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | claimed |
| US-12630821-B2 | Selective curbing of unwanted RNA editing (SECURE) DNA base editor variants | THE GENERAL HOSPITAL CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-20220073919-A1 | THERAPEUTIC OLIGONUCLEOTIDES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-10 | — | — | US | disclosed |
| JP-2005232181-A | ANTI-OSTEOPOROSIS DRUG | EISAI CO LTD | 2005-09-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485743-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | LMNA 2563/4885MAOB 2702/4885PTGS1 4442/4885 |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | LMNA 2563/4885MAOB 2702/4885PTGS1 4442/4885 |
| US-20250000817-A1 | Methods of Treating Mitochondrial Dysfunction | SLC25A20, NDUFAB1, HAGH | LMNA 411/4885MAOB 1111/4885PTGS1 1528/4885 |
| US-20250262169-A1 | METHODS OF TREATING COENZYME Q10 DEFICIENCY | NDUFB10, NDUFA10, NDUFB11 | LMNA 1283/4885MAOB 664/4885PTGS1 1676/4885 |
| US-12630821-B2 | Selective curbing of unwanted RNA editing (SECURE) DNA base editor variants | AMPD1, AMPD2, AMPD3 | LMNA 217/4885MAOB 688/4885PTGS1 4707/4885 |
| US-20220409554-A1 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | NQO1, SDHB, SDHA | LMNA 2639/4885MAOB 372/4885PTGS1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.